Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making

BACKGROUND: It is widely acknowledged that there is value in examining cancers for genomic aberrations via next-generation sequencing (NGS). How commercially available NGS platforms compare with each other, and the clinical utility of the reported actionable results, are not well known. During the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Glen J, Hoff, Brandi R, Whitehead, Robert P, Sangal, Ashish, Gingrich, Susan A, Penny, Robert J, Mallery, David W, Morris, Scott M, Thompson, Eric J, Loesch, David M, Khemka, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423502/
https://www.ncbi.nlm.nih.gov/pubmed/25960669
http://dx.doi.org/10.2147/OTT.S81995

Ejemplares similares

Ejemplares similares